Insmed Stock Soars on Breakthrough Lung Disease Drug Results
TL;DR
Insmed Incorporated's stock surged by up to 110% following positive study results for a drug treating bronchiectasis, a chronic lung condition. Analysts are optimistic about the company's future, with plans to file for U.S. market clearance and potential applications for other diseases.
Topics:businessbusinesspharmaceuticals#biotech#bronchiectasis#businesspharmaceuticals#insmed#stock-surge#study-results
- Insmed stock blasts off over lung condition study results Yahoo Finance
- Insmed Stock Surges on Trial Win for Lung-Condition Drug, a Possible Blockbuster Barron's
- Insmed CEO on lung disease treatment and path forward CNBC
- Insmed's shares double as lung disease med powers past expectations in phase 3 Fierce Biotech
- Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday? Yahoo Finance
Want the full story? Read the original reporting
Read on Yahoo Finance